ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
Featured Posts
    • Latest News
    Investors fret over durability of summer rally in US markets
    • August 19, 2022
    • Companies
    Privatising water was never going to work
    • August 19, 2022
    • Latest News
    Cineworld prepares for US bankruptcy filing
    • August 19, 2022
    • Companies
    WWE: body-slammed boss dives out as new champ grapples sale rumours
    • August 19, 2022
    • Markets
    Net zero targets: Ask what you can do for your country . . . 
    • August 19, 2022
Featured Categories
Belarussia
View Posts
Companies
View Posts
Energy
View Posts
Environment
View Posts
Food
View Posts
Governance
View Posts
Health
View Posts
Investors
View Posts
Latest News
View Posts
Markets
View Posts
Potash
View Posts
Regulators
View Posts
Russsia
View Posts
Social
View Posts
Supply Chain
View Posts
Sustainable Finance
View Posts
Technology
View Posts
Uncategorized
View Posts
ESG Telegraph ESG Telegraph
7K
9K
4K
1K
ESG Telegraph ESG Telegraph
  • Home
  • Latest News
  • Environment
  • Companies
  • Investors
  • Governance
  • Markets
  • Social
  • Regulators
  • Sustainable Finance
  • Latest News

GSK rejects Unilever’s £50bn offer for consumer unit

  • January 15, 2022
  • Staff
Total
0
Shares
0
0
0

GlaxoSmithKline has rejected a £50bn bid from Unilever to acquire its consumer health joint venture with Pfizer, saying it “fundamentally undervalued” the business and its future prospects.

GSK said it had turned down three approaches, including a £50bn offer comprising £41.7bn in cash and £8.3bn in Unilever shares, received on December 20.

“The board of GSK unanimously concluded that the proposals were not in the best interests of GSK shareholders as they fundamentally undervalued the Consumer Healthcare business,” the company said in a statement.

“The board of GSK therefore remains focused on executing its proposed demerger of the Consumer Healthcare business, to create a new independent global category-leading consumer company which, subject to approval from shareholders, is on track to be achieved in mid-2022.”

Unilever said earlier on Saturday that it had “approached GSK and Pfizer about a potential acquisition of the business”.

“GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to reshape its portfolio. There can be no certainty that any agreement will be reached,” Unilever added.

Unilever has made multiple attempts to engage with GSK over the past few months, making a number of approaches in that period, according to people with direct knowledge of the matter. GSK is working with Goldman Sachs.

The £50bn bid was first reported by the Sunday Times.

The prospect of a deal being reached depends on what the market and GSK believe is the value of the consumer business. Analyst estimates range from £37bn to £48bn for the unit. GSK said on Saturday that it expects the unit’s sales to grow 4 to 6 per cent over the medium term, at constant exchange rates.

Unilever declined to comment on whether it would return with a higher bid.

GSK has been preparing to spin off the division, a joint venture with Pfizer that makes Panadol painkillers, Theraflu cold and flu medicine, and Otrivin decongestant. The new company would be led by GSK insider Brian McNamara and its board is due to be chaired by Dave Lewis, the former Tesco and Unilever chief executive.

Activist investors including US hedge fund Elliott Management have put pressure on Emma Walmsley, GSK’s chief executive, to explore other options — including a sale — if it can generate greater returns for shareholders. Walmsley plans to use proceeds from the spin-off to bolster the pharma and drugs business’ lacklustre pipeline.

Marco Taricco, co-chief investment officer at Bluebell Capital Partners — one of the activist investors pushing for GSK to consider a sale of the unit — said the bid was “proof that such a high quality business has the potential to attract interest by strategic and financial buyers”. 

Pfizer owns 32 per cent of the division, which GSK has said it will list in London this year, although private equity groups have also looked at a potential purchase.

A Unilever buyout would be one of the largest ever on the London market, bringing together the FTSE 100’s third-largest company with a division that, if independent, would be in its top 20. It would be rivalled only by Vodafone’s acquisition of Germany’s Mannesmann in 1999 and AB InBev’s purchase of SABMiller in 2016.

The approach came as Unilever, already one of the world’s largest consumer goods groups, seeks to renew momentum after a period of tepid sales growth.

Its share price has languished since chief executive Alan Jope took over in 2019, and top-10 investor Terry Smith this week attacked the company as “labouring under the weight of a management which is obsessed with publicly displaying sustainability credentials at the expense of focusing on the fundamentals of the business”.

Other investors disputed that, but most agree the company must address its underperformance. It agreed last year to sell off its tea division, which has been a drag on growth, for €4.5bn to private equity group CVC, but has yet to make a major acquisition under Jope.

Unilever in 2018 agreed a deal to buy GSK’s health food drinks business, including the Horlicks brand, in India and other Asian markets for €3.3bn. It has also acquired a series of small consumer health brands, including Smarty Pants, Olly and Onnit supplements and Liquid IV drinks mixes.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
You May Also Like
Read More
  • Latest News

Investors fret over durability of summer rally in US markets

  • Staff
  • August 19, 2022
Read More
  • Latest News

Cineworld prepares for US bankruptcy filing

  • Staff
  • August 19, 2022
Read More
  • Latest News

UK health body calls for upgrade to sewage system as beaches close

  • Staff
  • August 19, 2022
Read More
  • Latest News

Italy election frontrunner Giorgia Meloni says she will not put Covid funds at risk

  • Staff
  • August 19, 2022
Read More
  • Latest News

Air travel chaos begins to ease but is there more trouble on the horizon?

  • Staff
  • August 19, 2022
Read More
  • Latest News

Starling Bank’s Anne Boden: ‘I was ashamed to be a banker’

  • Staff
  • August 19, 2022
Read More
  • Latest News

Trump’s turmoil poses a conundrum for Republicans

  • Staff
  • August 19, 2022
Read More
  • Latest News

Chinese tycoon Xiao Jianhua sentenced to 13 years in jail for financial crimes

  • Staff
  • August 19, 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Featured Posts
  • 1
    Investors fret over durability of summer rally in US markets
    • August 19, 2022
  • 2
    Privatising water was never going to work
    • August 19, 2022
  • 3
    Cineworld prepares for US bankruptcy filing
    • August 19, 2022
  • 4
    WWE: body-slammed boss dives out as new champ grapples sale rumours
    • August 19, 2022
  • 5
    Net zero targets: Ask what you can do for your country . . . 
    • August 19, 2022
Recent Posts
  • UK health body calls for upgrade to sewage system as beaches close
    • August 19, 2022
  • How Tiger Global withdrew its claws when the tech bubble burst
    • August 19, 2022
  • More smelters face threat of closure as Europe enters a power-starved winter
    • August 19, 2022

Sign Up for Our Newsletters

Subscribe now to our newsletter

ESG Telegraph
  • Home
  • Privacy Policy
  • Guest Post
  • Contact

Input your search keywords and press Enter.